IL1-RN Gene and Prostate Cancer Risk
Author Information
Author(s): Lindmark F, Zheng S L, Wiklund F, Bälter K A, Sun J, Chang B, Hedelin M, Clark J, Johansson J-E, Meyers D A, Adami H-O, Isaacs W, Grönberg H, Xu J
Primary Institution: Umeå University
Hypothesis
Sequence variants in the IL1-RN gene are associated with prostate cancer risk.
Conclusion
The study found that the ATGC haplotype in the IL1-RN gene is associated with an increased risk of prostate cancer, particularly in advanced cases.
Supporting Evidence
- The prevalence of the ATGC haplotype was significantly higher among prostate cancer cases compared to controls.
- Homozygous carriers of the ATGC haplotype had an increased risk of prostate cancer with an odds ratio of 1.6.
- The association was stronger in cases with advanced prostate cancer, with an odds ratio of 1.8.
Takeaway
Researchers looked at a gene related to inflammation to see if it affects prostate cancer risk, and they found that a specific gene variant is linked to a higher chance of getting the disease.
Methodology
A population-based case-control study was conducted with genotyping of SNPs in the IL1-RN gene among prostate cancer patients and control subjects.
Potential Biases
Potential bias due to population stratification was minimized by matching controls based on age and geographic origin.
Limitations
The study is limited to a Swedish population, which may affect the generalizability of the findings.
Participant Demographics
The study included 1383 prostate cancer patients and 779 control subjects, with a mean age of 66.6 years for cases and 67.9 years for controls.
Statistical Information
P-Value
0.009
Confidence Interval
1.2–2.2
Statistical Significance
p=0.009
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website